Wu Gong and fellow researchers will report results of the PROTECT clinical trial in IgA nephropathy (IgAN) during the National Kidney Foundation Spring Clinical Meetings. The trial evaluated the long-term nephroprotective potential of sparsentan (SPAR) versus maximally titrated irbesartan (MT-IRB). PROTECT compared 2-year estimated glomerular filtration rate (eGFR) total slopes between the SPAR and MT-IRB groups and standard of care (SoC) in the following populations with similar eligibility criteria: a real-world data setting (UK National Registry of Rare Kidney Diseases [RaDaR] patients with IgAN) and a comparable clinical trial population ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Researchers studied the relationship between CKD and serum urate by assessing stage prevalence after first gout diagnosis.
A group of kidney care experts proposed a new transplant-inclusive value-based care model to better incentivize transplant.
There are few data on differences in serum creatinine concentration between Black and non-Black patients.
Clinical research entity American Clinical Research Services (ACRS) has acquired clinical trial site network Elixia.
The HHS has proposed a new mandatory model to increase access to kidney transplants, beginning January 1, 2025.
There are few data on whether finerenone-induced change in UACR mediates cardiovascular and kidney failure outcomes.
Thermo Fisher Scientific has launched the CXCL10 testing service to help in the management of kidney transplant patients.
AI technology to detect elevated CKD risk in people with diabetes received Breakthrough Device designation from the FDA.
Value-based kidney care provider Evergreen Nephrology has added two new executives to its leadership team.
How does sodium bicarbonate affect bone health markers in patients with chronic kidney disease (CKD)?
Advertisement
Expert Interviews
In Print
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Special issue discusses racial inequity in living donor kidney transplant, teen BMI and CKD risk, and more
Conferences
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
Podcasts
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Review Dr. Burton Rose's writings on treatment options for hypovolemic states and hypovolemic shock.
Expert Columns
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
